The product is disappearing into reorder rhythm: revenue is shifting from won-each-time to arriving-on-its-own, and the
The model's full reasoning — Q3 2023 call → NOWe need answer only YES or NO. Need evaluate transcript. Question asks: does management describe that a growing share of revenue now arrives without a new selling event — through reorders, refills, renewals, repeat purchases, usage-driven billing, aftermarket or consumable pull-through, or customers' own standing routines — AND that this self-arriving share has recently and visibly grown as proportion of business, with management grounding shift in observed current behavior and treating it as changing quality of revenue? We need use only transcript. Need determine if management describes such. Let's parse. Company sells FUROSCIX, a drug product. Revenue from prescriptions filled. They report prescriptions, unique prescribers, doses per prescription. They mention repeat? They mention "refills"? They mention "reorders"? They mention "customers' own standing routines"? They mention "in-services" and new territories. They mention "pending prescriptions" and "filled". They mention "average number of doses per prescription filled was 5.6, which remains higher than long-term expectations." They mention "direct sales to IDNs" and "IDN" agreements. They mention "unrestricted access" and "fixed copay". They mention "payer decisions expand population". They mention "lifecycle management" etc. Question specifically about self-arriving revenue: reorders, refills, renewals, repeat purchases, consumable pull-through, usage growth from installed product, customers reordering on own schedule. Does management describe that? They talk about prescriptions written and filled. They talk about "pending prescriptions" and "queued" for future use. They talk about doctors ordering product in advance of needing it, having it ready in queue until they want to release to patient. That is not exactly self-arriving revenue? It is prescriptions written, then filled when patient needs. But revenue occurs when filled. They mention "we continue to fill more pending prescriptions written in Q3 into the filled category every day." That is not repeat purchases? It's backlog. They mention "doses per prescription" and "quantity limits". They mention "refills"? Not explicitly. They mention "repeat behavior"? They mention "unique prescribers" increasing, "total prescribers", "in-services".
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
DUOT · Q4 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, through reorders, renewals, etc., and that this has recently and visibly grown as a ...
QTRX · Q3 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through reorders, consumables, etc., and that this share has recently grown.
CYBR · Q3 2021 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through renewals, and that this has recently grown as a proportion.